Is IDRSF or CL a better dividend investment in 2026?

IDRSF currently yields 48.90% with a 5% 5-year dividend growth rate. CL yields 4.00% with 5% growth. The better choice depends on your goal: IDRSF offers higher current income.

What is the dividend yield difference between IDRSF and CL?

IDRSF has a forward dividend yield of 48.90% ($2.00/share annually). CL yields 4.00% ($2.00/share annually). The yield gap is 44.90 percentage points.

Home › Compare › IDRSF vs CL

IDRSF vs CL: Dividend Comparison 2026

IDRSF yields 48.90% · CL yields 4.00%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 IDRSF wins by $344.1K in total portfolio value

INVESTMENT

TIME HORIZON10 years

IDRSF

● Live price

48.90%

Share price

$4.09

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$372.2K

Annual income

$74,100.38

Full IDRSF calculator →

● Live price

4.00%

Share price

$50.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$28.0K

Annual income

$899.19

Full CL calculator →

Portfolio growth — IDRSF vs CL

📍 IDRSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	IDRSF	CL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, IDRSF + CL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

IDRSF pays

CL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IDRSF

Annual income on $10K today (after 15% tax)

$4,156.48/yr

After 10yr DRIP, annual income (after tax)

$62,985.32/yr

Annual income on $10K today (after 15% tax)

$340.00/yr

After 10yr DRIP, annual income (after tax)

$764.31/yr

At 15% tax rate, IDRSF beats the other by $62,221.01/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IDRSF + CL for your $10,000?

IDRSF: 50%CL: 50%

100% CL50/50100% IDRSF

Portfolio after 10yr

$200.1K

Annual income

$37,499.79/yr

Blended yield

18.74%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

IDRSF

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-10.1

Piotroski

3/9

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$92.45

+84.9% upside vs current

Range: $85.00 — $100.00

Altman Z

4.5

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IDRSF buys

CL buys

No recent congressional trades found for IDRSF or CL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricIDRSFCL

Forward yield	48.90% ✓	4.00%
Annual dividend / share	$2.00	$2.00
Payout ratio	50%	50%
1-year div growth	0%	5% ✓
5-year div CAGR	0%	5% ✓
Portfolio after 10y	$372.2K ✓	$28.0K
Annual income after 10y	$74,100.38 ✓	$899.19
Total dividends collected	$295.4K ✓	$6.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples
Analyst consensus	Buy	Hold

Year-by-year: IDRSF vs CL ($10,000, DRIP)

Year	IDRSF Portfolio	IDRSF Income/yr	CL Portfolio	CL Income/yr	Gap
1← crossover	$15,590	$4,889.98	$11,120	$420.00	+$4.5K → IDRSF
2	$23,806	$7,124.73	$12,357	$458.31	+$11.4K → IDRSF
3	$35,640	$10,167.77	$13,721	$499.76	+$21.9K → IDRSF
4	$52,361	$14,226.41	$15,227	$544.58	+$37.1K → IDRSF
5	$75,560	$19,533.63	$16,885	$593.02	+$58.7K → IDRSF
6	$107,194	$26,344.00	$18,713	$645.34	+$88.5K → IDRSF
7	$149,625	$34,927.92	$20,724	$701.81	+$128.9K → IDRSF
8	$205,663	$45,564.28	$22,938	$762.73	+$182.7K → IDRSF
9	$278,591	$58,531.92	$25,372	$828.41	+$253.2K → IDRSF
10	$372,193	$74,100.38	$28,047	$899.19	+$344.1K → IDRSF

IDRSF vs CL: Complete Analysis 2026

IDRSF — Stock

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Full IDRSF Calculator →

CL — Consumer Staples

CL is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in CL shares.

Full CL Calculator →

📬

Get this IDRSF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IDRSF vs SCHD IDRSF vs JEPI IDRSF vs O IDRSF vs KO IDRSF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.